The challenges brought on by the COVID-19 pandemic have placed greater importance on risk management, and have required clinical trial sponsors and CROs to adopt risk-based quality management (RBQM) methodologies for clinical trial execution to:

• ensure the safety of trial participants
• maintain compliance with good clinical practice
• minimize risks to trial integrity

Many have recognized great improvements in trial execution and operational efficiencies with this adoption, while others are struggling with how to implement RBQM. Read this white paper to learn the current state of RBQM approaches to providing decentralized trial oversight, and the value that adopting these approaches brings to sponsors, CROs, sites, and ultimately patients.